Safety Aspects of DIMS Technology Glasses, Fixation as a Marker for Amblyopia, Bielschowsky Head Tilt Test in Superior Oblique Paresis and Successful Late Topical Treatment of Orbital Infantile Hemangioma

Progressive childhood myopia has become a significant issue in East and Southeast Asia over the last 60 years and is associated with the risk of visual acuity degradation down to severe impairment or blindness [1], [2]. Over the last decade, various attempts to prevent excessive eye growth have been undertaken. These include the local application of atropine, which has long been known for its potential of lowering the eye growth rate. However, higher dosages (0.5% or higher) have significant side effects such as photophobia and decreased accommodation as well as a significant rebound of myopia on discontinuation. Low-dose atropine (0.01%) has been shown to be effective in a dose-dependent manner with little side effects and less profound rebound and thus has become the most common pharmacological treatment of childhood myopia [3], [4], [5]. Another approach targets the dependency of eyeball growth on defocus. Initial studies deploying spectacle lens designs intended to reduce peripheral hyperopic defocus could not show significant differences in the rate of myopia progression after 1 year when compared to a standard control lens. There was significantly less progression only for participants with a family history of myopia [6]. Recently, two new lens designs have been developed: Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslet Target (H. A. L. T.) technology spectacle lenses. Both designs aim to slow down or stop eye growth by means of a peripheral retinal myopic defocus [7]. While DIMS technology creates a simultaneous defocus by incorporating a central zone for distance refractive correction and a zone of multiple defocus segments (lenslets) of + 3.5 D surrounding the central zone [8], the H. A. L. T. technology provides a volume of myopic defocus (VoMD) through 11 concentric rings of contiguous lenslets [9]. For both lens designs, a significant slowdown of myopia progression and axial elongation has been shown in recent studies [8], [9], [10], [11]. In cases in which one method alone does not stop or significantly slow progression, a combination of atropine and DIMS or H. A. L. T. spectacle lenses may be applied. Despite intermittent perception of peripheral defocus, good tolerance and acceptance has been shown for DIMS lenses [12]. However, both treatments may substantially alter visual performance required for driving or participation in road traffic. Kaymak et al. therefore studied the impact of the combination of DIMS spectacle lenses and low-dose atropine (0.01%) on pupil and visual functions, including visual acuity, photopic and mesopic contrast sensitivity, mesopic vision, and glare sensitivity [13]. Looking through the lenslets area and atropine reduced visual acuity by 0.24 and 0.27 logMAR, respectively. The combination reduced visual acuity by 0.33 logMAR. Additional glare induced no additional reduction. While contrast sensitivity reduction increases with spatial frequency when looking through the lenslets area, additional atropine treatment did not show any additional effect. Pupil function was significantly reduced even 8 hours after atropine application. Even though under no condition did visual acuity drop below 0.3 logMAR and no other clinical relevant restriction of visual functions were found in this study, it has to be kept in mind that children concerned may be at risk from additional amblyopia or subnormal visual function.

Publikationsverlauf

Artikel online veröffentlicht:
18. Oktober 2022

• References

• 1 Spillmann L. Stopping the rise of myopia in Asia. Graefes Arch Clin Exp Ophthalmol 2020; 258: 943-959 DOI: 10.1007/s00417-019-04555-0.
• 2 Lagrèze WA, Joachimsen L, Schaeffel F. Gegenwärtiger Stand der Empfehlungen zur Minderung von Myopieprogression. Ophthalmologe 2017; 114: 24-29 DOI: 10.1007/s00347-016-0346-1.
• 3 Schittkowski MP, Sturm V. Atropin zur Prävention der Myopieprogression – Datenlage, Nebenwirkungen, praktische Empfehlungen. Klin Monbl Augenheilkd 2018; 235: 385-391 DOI: 10.1055/s-0043-121982.
• 4 Tran HDM, Tran YH, Tran TD. et al. A Review of Myopia Control with Atropine. J Ocul Pharmacol Ther 2018; 34: 374-379 DOI: 10.1089/jop.2017.0144.
• 5 Wu PC, Chuang MN, Choi J. et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond) 2019; 33: 3-13 DOI: 10.1038/s41433-018-0139-7.
• 6 Huang J, Wen D, Wang Q. et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Ophthalmology 2016; 123: 697-708 DOI: 10.1016/j.ophtha.2015.11.010.
• 7 Smith III EL, Arumugam B, Hung LF. et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res 2020; 177: 32-40 DOI: 10.1016/j.visres.2020.08.003.
• 8 Lam CSY, Tang WC, Tse DYY. et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol 2020; 104: 363-368 DOI: 10.1136/bjophthalmol-2018-313739.
• 9 Bao J, Yang A, Huang Y. et al. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol 2022; 106: 1171-1176 DOI: 10.1136/bjophthalmol-2020-318367.
• 10 Bao J, Huang Y, Li X. et al. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs. Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol 2022; 140: 472-478 DOI: 10.1001/jamaophthalmol.2022.0401.
• 11 Lam CS, Tang WC, Lee PH. et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. Br J Ophthalmol 2022; 106: 1110-1114 DOI: 10.1136/bjophthalmol-2020-317664.
• 12 Lu Y, Lin Z, Wen L. et al. The Adaptation and Acceptance of Defocus Incorporated Multiple Segment Lens for Chinese Children. Am J Ophthalmol 2020; 211: 207-216 DOI: 10.1016/j.ajo.2019.12.002.
• 13 Kaymak H, Mattern AI, Graff B. et al. Sicherheit von Brillengläsern mit DIMS-Technologie und Atropin in der Kombinationstherapie der Myopieprogression. Klin Monbl Augenheilkd 2022; 239: 1197-1205 DOI: 10.1055/a-1930-7116.
• 14 Carpineto P, Ciancaglini M, Nubile M. et al. Fixation patterns evaluation by means of MP-1 microperimeter in microstrabismic children treated for unilateral amblyopia. Eur J Ophthalmol 2007; 17: 885-890 DOI: 10.1177/112067210701700603.
• 15 Subramanian V, Jost RM, Birch EE. A quantitative study of fixation stability in amblyopia. Invest Ophthalmol Vis Sci 2013; 54: 1998-2003 DOI: 10.1167/iovs.12-11054.
• 16 Irsch K, Guyton DL, Ying HS. Disconjugacy of eye movements during attempted fixation: a sufficient marker for amblyopia?. Klin Monbl Augenheilkd 2022; 239: 1206-1212 DOI: 10.1055/a-1933-3150.
• 17 Zhou Y, Bian H, Yu X. et al. Quantitative assessment of eye movements using a binocular paradigm: comparison among amblyopic, recovered amblyopic and normal children. BMC Ophthalmol 2022; 22: 365 DOI: 10.1186/s12886-022-02579-5.
• 18 Scott AB. Extraocular muscles and head tilting. Electromyographic measurement of activity of individual muscles. Arch Ophthalmol 1967; 78: 397-399 DOI: 10.1001/archopht.1967.00980030399024.
• 19 Muthusamy B, Irsch K, Peggy Chang HY. et al. The sensitivity of the bielschowsky head-tilt test in diagnosing acquired bilateral superior oblique paresis. Am J Ophthalmol 2014; 157: 901-907.e2 DOI: 10.1016/j.ajo.2014.01.003.
• 20 Irsch K, Guyton DL, Ying HS. How lingering fusional adaptation influences the Bielschowsky head tilt test in superior oblique paresis. Klin Monbl Augenheilkd 2022; 239: 1213-1220 DOI: 10.1055/a-1933-3223.
• 21 Low CM, Stokken JK. Typical Orbital Pathologies: Hemangioma. J Neurol Surg B Skull Base 2021; 82: 20-26 DOI: 10.1055/s-0040-1722633.
• 22 Hildebrand GD, Sipkova Z. Topical Timolol for Infantile Haemangioma of the Orbit. Klin Monbl Augenheilkd 2021; 238: 1069-1076 DOI: 10.1055/a-1645-1665.
• 23 Léauté-Labrèze C, Dumas de la Roque E, Hubiche T. et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651 DOI: 10.1056/NEJMc0708819.
• 24 Prey S, Voisard JJ, Delarue A. et al. Safety of Propranolol Therapy for Severe Infantile Hemangioma. JAMA 2016; 315: 413-415 DOI: 10.1001/jama.2015.13969.
• 25 Hildebrand GD, Sipkova Z. Successful late treatment of orbital infantile haemangiomas in two teenagers with topical transcutaneous timolol maleate 0.5 % alone. Klin Monbl Augenheilkd 2022; 239: 1221-1231 DOI: 10.1055/a-1936-3531.